Advertisement
Advertisement
TENX
Tenax Therapeutics, Inc.
1.69
USDSponsored
+0.06
+3.68%
Nov 06, 15:48 UTC -5
Closed
After-Market
1.69
0.00
0.00%
Tenax Therapeutics, Inc. (TENX) Earnings
TENX Earnings Reports
Positive Surprise Ratio
TENX beat 24 of 41 last estimates.
59%
Next Report
Date of Next Report
Mar 08, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.36
Implied change from Q3 26 (Revenue/ EPS)
--
/+16.13%
Implied change from Q4 25 (Revenue/ EPS)
--
/-5.26%
Tenax Therapeutics, Inc. earnings per share and revenue
On Nov 05, 2026, TENX reported earnings of -0.31 USD per share (EPS) for Q3 26, beating the estimate of -0.36 USD, resulting in a 15.58% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -9.94% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.36 USD, with revenue projected to reach -- USD, implying an increase of 16.13% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunocore Holdings plc - ADR
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.28
Surprise
-104.08%
Entera Bio Ltd. Ordinary Shares
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.06
Actual
-$0.11
Surprise
-58.50%
Vogenx Inc Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.47
Surprise
-187.99%
Agenus Inc.
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.27
Actual
$0.02
Surprise
+107.26%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
-$0.02
Surprise
-132.68%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Bio-Techne Corp.
Report Date
Nov 06, 2026 For Q1 27
Estimate
$0.44
Actual
$0.44
Surprise
-1.96%
Aligos Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$2.21
Actual
-$2.09
Surprise
+5.58%
CervoMed Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.39
Surprise
+21.97%
Creative Medical Technology Holdings, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.40
Surprise
-63.40%
FAQ
What were Tenax Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Tenax Therapeutics, Inc. reported EPS of -$0.31, beating estimates by 15.58%, and revenue of $0.00, 0% as expectations.
How did the market react to Tenax Therapeutics, Inc.'s Q3 2026 earnings?
The stock price moved down -9.94%, changed from $1.81 before the earnings release to $1.63 the day after.
When is Tenax Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Mar 08, 2027.
What are the forecasts for Tenax Therapeutics, Inc.'s next earnings report?
Based on --
analysts, Tenax Therapeutics, Inc. is expected to report EPS of -$0.36 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.